You are here

Vertex Pharmaceuticals

This FDA Nod Is a Game Changer for Patients: Could It Equal Billions for Vertex Pharmaceuticals?

This FDA Nod Is a Game Changer for Patients: Could It Equal Billions for Vertex Pharmaceuticals?

Motley Fool

Vertex Pharmaceuticals

cystic fibrosis

Flag link:

Finding the big spenders beyond big pharma

Finding the big spenders beyond big pharma

EP Vantage

Gilead Sciences

Moderna Therapeutics

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Flag link:

Could This Move Make Vertex's Next Blockbuster Even Bigger?

Could This Move Make Vertex's Next Blockbuster Even Bigger?

Motley Fool

Vertex Pharmaceuticals

beta thalassemia

sickle cell disease

Flag link:

Gene Editing Therapeutics Could Hit the Market in 2023

Gene Editing Therapeutics Could Hit the Market in 2023

BioSpace

CRISPR Therapeutics

Vertex Pharmaceuticals

Intellia Therapeutics

Editas Medicine

Beam Therapeutics

Flag link:

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Yahoo/Businesswire

Vertex Pharmaceuticals

CRISPR Therapeutics

sickle cell disease

beta thalassemia

Flag link:

Vertex ponies up $100M for CRISPR's gene editing tech to develop new diabetes modality

Vertex ponies up $100M for CRISPR's gene editing tech to develop new diabetes modality

Endpoints

Vertex Pharmaceuticals

CRISPR Therapeutics

Flag link:

Vertex flexes its dealmaking muscle

Vertex flexes its dealmaking muscle

EP Vantage

Vertex Pharmaceuticals

Entrada Therapeutics

Tevard Biosciences

Duchenne Muscular Dystrophy

Flag link:

Vertex's next off-the-shelf diabetes cell therapy follows in predecessor's footsteps to the clinic

Vertex's next off-the-shelf diabetes cell therapy follows in predecessor's footsteps to the clinic

Fierce Biotech

Vertex Pharmaceuticals

type 1 diabetes

Flag link:

Vertex pays ImmunoGen $15M to use antibody-drug conjugates to improve CRISPR therapy

Vertex pays ImmunoGen $15M to use antibody-drug conjugates to improve CRISPR therapy

Fierce Biotech

Vertex Pharmaceuticals

antibody-drug conjugate

Flag link:

Vertex tiptoes further into Duchenne research with Tevard deal

Vertex tiptoes further into Duchenne research with Tevard deal

BioPharma Dive

Vertex Pharmaceuticals

Duchenne Muscular Dystrophy

Tevard Biosciences

Flag link:

Spotlight – Cystic fibrosis developers take a deep breath

Spotlight – Cystic fibrosis developers take a deep breath

EP Vantage

cystic fibrosis

Vertex Pharmaceuticals

4D Molecular Therapeutics

Arcturus Therapeutics

Arrowhead Pharmaceuticals

Boehringer Ingelheim

Eloxx Pharmaceuticals

Krystal Biotech

Moderna Therapeutics

Oxford BioMedica

ReCode Therapeutics

Sumitomo Pharmaceuticals

Tessera Therapeutics

Flag link:

Medicaid, with planned payment pilot, girds for influx of pricey gene therapies

Medicaid, with planned payment pilot, girds for influx of pricey gene therapies

BioPharma Dive

sickle cell disease

Vertex Pharmaceuticals

CRISPR Therapeutics

Flag link:

‘Caught in the middle’: A battle between Vertex and insurers is leaving cystic fibrosis patients with crushing drug costs

‘Caught in the middle’: A battle between Vertex and insurers is leaving cystic fibrosis patients with crushing drug costs

Stat

Vertex Pharmaceuticals

cystic fibrosis

Flag link:

Vertex Teases Launch of Landmark CRISPR Therapy

Vertex Teases Launch of Landmark CRISPR Therapy

BioSpace

Vertex Pharmaceuticals

sickle cell disease

Flag link:

Vertex pricing under fire—again—as activists press 4 governments for Trikafta generics

Vertex pricing under fire—again—as activists press 4 governments for Trikafta generics

Fierce Pharma

Vertex Pharmaceuticals

cystic fibrosis

Flag link:

Led by Merck, Vertex and Lilly, pharma's share prices largely climbed in '22 despite economic angst

Led by Merck, Vertex and Lilly, pharma's share prices largely climbed in '22 despite economic angst

Fierce Pharma

Vertex Pharmaceuticals

Flag link:

EMA validates Vertex's CRISPR application, clearing barrier on road to landmark approval

EMA validates Vertex's CRISPR application, clearing barrier on road to landmark approval

Fierce Biotech

Vertex Pharmaceuticals

CRISPR Therapeutics

sickle cell disease

Flag link:

Pages